

CITATION REPORT

List of articles citing

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged > 50 Years in Japan: Results of a Markov Model Analysis

DOI: 10.1007/s13555-018-0236-3

Dermatology and Therapy, 2018, 8, 269-284.

Source: <https://exaly.com/paper-pdf/68877874/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. <i>Infection and Drug Resistance</i> , 2018 , 11, 1401-1411	4.2	6
11	Community-acquired acute meningitis and encephalitis: a narrative review. <i>Medical Journal of Australia</i> , 2018 , 209, 449-454	4	8
10	Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. <i>Vaccine</i> , 2019 , 37, 3588-3597	4.1	5
9	Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older. <i>Dermatology and Therapy</i> , 2019 , 9, 281-297	4	5
8	The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2020 , 16, 327-334	4.4	3
7	Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. <i>Journal of Dermatology</i> , 2020 , 47, 236-244	1.6	4
6	Efficacy and safety of pulsed radiofrequency modulation of thoracic dorsal root ganglion or intercostal nerve on postherpetic neuralgia in aged patients: a retrospective study. <i>BMC Neurology</i> , 2021 , 21, 233	3.1	2
5	Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 3735-3746	4.4	2
4	The Number Needed to Vaccinate (NNV) against herpes zoster: a systematic review with meta-analysis.. <i>Infectious Diseases</i> , 2021 , 1-11	3.1	
3	Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. <i>Dermatology and Therapy</i> , 2022 , 12, 1447-1467	4	2
2	How large could the public health impact of introducing recombinant zoster vaccination for people aged 50 years in five Latin American countries be?. 2023 , 19,		0
1	Public health impact of herpes zoster vaccination on older adults in Hong Kong. 2023 , 19,		0